骨科新手通常对 Orthopaedics与Orthopedics的区别抱有疑问,现将其Google如下: Why we use the spelling Orthopaedics instead of Orthopedics? Is the word “Orthopaedic” or “Orthopedic” spelled correctly? The right answer is that they both are, however we use the former in the name of our group Atlantic Orthopaedic Specialists for a number of reasons. Nicholas Andry “the Father of Orthopaedics” first used the term in 1741 when he published “Orthopaedia or The Art of Correcting and Preventing Deformities in Children”. The word Orthopaedic is derived from the Greek word “orthos” meaning to straighten and “paidion” signifying children. In early years, the specialty of Orthopaedics focused primarily on the correction of childhood musculoskeletal deformities such as polio, rickets, and scoliosis. This spelling is also used to distinguish it from other specialties such as pediatrics and podiatry, since in Latin “pedis” means foot and in Greek “pod” represents the foot. Today, the specialty of Orthopaedics is the branch of medicine that deals exclusively with the diagnosis and treatment of injuries and disorders of the musculoskeletal system. The American Academy of Orthopaedic Surgeons founded in 1933 is the main provider of education to Orthopaedic Surgeons and other healthcare providers seeking information on musculoskeletal conditions and their treatment. We take great pride in our profession and in the care we give to our patients and so we use the original spelling to represent a firm commitment to our chosen specialty and its future. http://www.atlanticortho.com/orthopedic.aspx 1. Orthopaedics和Orthopedics读音一样,英音与美音略有区别,英音: ,美音: 。 2. Orthopaedics是传统的拼写方式。由Nicholas Andry在1741年他的著作“Orthopaedia: or the Art of Correcting and Preventing Deformities in Children.”里第一次使用,词根"orthos"意指矫正, "paideion" 指儿童。其原意是指儿童矫形的研究。 3. Orthopedics指关于骨骼肌肉系统的研究。 美国使用orthopedic比较多,而世界上其他的国家,地区通常使用传统的orthopaedic这种拼写。但是官方的一些项目,大学,甚至美国骨科医生协会,美国骨科学会使用的都是传统的orthopaedic拼写方式。
分享一下2012年5月16日Biotronik公司在其网站上发布他们对镁合金药物洗脱支架的12个月临床(欧洲多中心,6个月和12个月2组共46个患者)随访结果,与去年发布的6个月结果相比,Twelve-month results from the BIOSOLVE-I study with the DRug Eluting Absorbable Metal Scaffold (DREAMS) demonstrate safety and confirm vessel vasomotion.这对做可降解金属的同仁们会是个鼓励。 pdf下载在这里 BIOTRONIK_PR%20BIOSOLVE-I_EuroPCR_EN.pdf http://www.biotronik.de/wps/wcm/connect/int_web/biotronik/newsroom/press_releases?p=http://www.biotronik.de/wps/wcm/connect/int_web/biotronik/newsroom/press_releases/press_release_biosolve_ipw=770pt = At one year, DREAMS demonstrated a low 7.0% rate of target lesion failure with no death or scaffold thrombosis. The target lesion revascularization rate was 4.7%. The analysis showed an in-scaffold late lumen loss of 0.52 mm, which was further reduced from the 6-month results. Vasoreactivity at 12 months did not significantly change from the 6-month results, suggesting that the natural physiology of the vessels was already restored after 6 months of healing and could be sustained. “The reduction of the 12-month late lumen loss is likely due to plaque regression and late expansive remodeling. At 6 months, we have already seen that vasomotion is restored, so the new results verify that the vessels are naturally adapting to accommodate flow,” said Professor Haude. “Additionally, we could further validate that the return of natural vessel angulation that we saw at 6 months was maintained also at 12 months. These results suggest a real restoration of the vessel’s natural architecture.” DREAMS is made of a proprietary magnesium alloy coated with a matrix of a bioabsorbable polymer and paclitaxel to inhibit neointimal cell proliferation within the first few months after scaffold implantation. Mechanical properties of the magnesium alloy allow deployment of the device to be comparable to conventional metallic stents. “The particularly positive feature of the magnesium scaffold is its nice conformability to the vessel wall. A few months after DREAMS implantation, the artery is able to regain its original shape and physiology. This is the main benefit of the magnesium scaffold over the more rigid polymer-based platforms,” Professor Haude added. “These positive one-year results confirm that we are working in the right direction. BIOTRONIK continues to invest in our DREAMS program as we believe that bringing vascular restoration therapy to patients without changing the way physicians implant a scaffold is important to the adoption of this technology,” stated Alain Aimonetti, Vice President of Sales and Marketing at BIOTRONIK Vascular Intervention. “An improvement of late lumen loss between 6 and 12 months shows us that the values become more predictable over time. It makes sense, especially for the bioabsorbable scaffolds, to focus on long-term outcomes and not so much on short-term results,” Aimonetti concluded. “We see huge potential for DREAMS since it combines deployment and postdilatation properties and long-term outcomes comparable to DES with the additional benefits of vascular restoration therapy. About the BIOSOLVE-I Clinical Trial The BIOSOLVE-I first-in-man study is a prospective, multicenter, nonrandomized, European, first-in-man clinical trial evaluating the safety and efficacy of DREAMS. Forty-six patients were enrolled in two cohorts that evaluated the primary endpoint of target lesion failure (TLF) at 6 months for cohort 1 and at 12 months for cohort 2. About the DRug Eluting Absorbable Metal Scaffold (DREAMS) DREAMS is part of a revolutionary new treatment option for patients with coronary artery disease . In contrast to existing permanent stents, this device is based on a slow-absorbing, high-strength magnesium backbone. The vessel is not caged as it would be with a permanent implant, thus the artery is able to resume its natural physiology. This novel treatment concept opens a new area of vascular restoration therapy. Properties of the proprietary magnesium alloy allow a straightforward deployment of the device, comparable to conventional metallic stents. BIOTRONIK’s DREAMS is coated with antiproliferative paclitaxel to inhibit excess tissue growth during the healing process. The company has announced next-generation platforms under development using the BIOlute coating from the Orsiro hybrid drug-eluting stent featuring sirolimus as the active compound. About BIOTRONIK SE Co. KG As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5,600 employees. Known for having its fingers on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face and provides the best solutions for all phases of patient care, ranging from diagnosis and treatment to patient management. Quality, innovation and clinical excellence define BIOTRONIK and its growing success—and deliver confidence and peace of mind to physicians and their patients worldwide.